The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer.
10.3904/kjim.2013.28.4.449
- Author:
Kyoung Ju LEE
1
;
Eun Joo LEE
;
Gyu Young HUR
;
Sang Yeub LEE
;
Je Hyeong KIM
;
Chol SHIN
;
Jae Jeong SHIM
;
Kwang Ho IN
;
Kyung Ho KANG
;
Se Hwa YOO
;
Sung Yong LEE
Author Information
1. Division of Respiratory and Allergy, Department of Internal Medicine, Daejin Medical Center, Seongnam, Korea.
- Publication Type:Original Article
- Keywords:
Small cell lung carcinoma;
Limited-stage;
Chemoradiotherapy;
Start of any treatment until the end of radiotherapy
- MeSH:
Aged;
*Chemoradiotherapy;
Chi-Square Distribution;
Female;
Humans;
Kaplan-Meier Estimate;
Lung Neoplasms/mortality/pathology/*therapy;
Male;
Middle Aged;
Neoplasm Staging;
Odds Ratio;
Proportional Hazards Models;
Retrospective Studies;
Small Cell Lung Carcinoma/mortality/pathology/*surgery;
Time Factors;
Treatment Outcome
- From:The Korean Journal of Internal Medicine
2013;28(4):449-455
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Chemotherapy combined with radiation therapy is the standard treatment for limited stage small cell lung cancer (LS-SCLC). Although numerous studies indicate that the overall duration of chemoradiotherapy is the most relevant predictor of outcome, the optimal chemotherapy and radiation schedule for LS-SCLC remains controversial. Therefore we analyzed the time from the start of any treatment until the end of radiotherapy (SER) in patients with LS-SCLC. METHODS: We retrospectively analyzed 29 patients diagnosed histologically with LS-SCLC and divided them into two groups: a short SER group (< 60 days) and a long SER (> 60 days) group. Patients were treated with irinotecan-based chemotherapy and thoracic radiotherapy. RESULTS: Sixteen patients were in the short SER group and 13 patients were in the long SER group. Short SER significantly prolonged survival rate (p = 0.03) compared with that of long SER. However, no significant differences in side effects were observed. CONCLUSIONS: Short SER should be considered to improve the outcome of concurrent chemoradiotherapy for LS-SCLC.
